Immunovant, Inc.

IMVT· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$38.51-0.28%

2026-08-03

Financials

Valuation Metrics

Immunovant, Inc.'s Market Cap is $7.91B. At end of 2025 it was $4.61B. Ranked #1079 of 3,112 in US market (top 35%), #357 of 1,445 on NASDAQ (top 25%), #57 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$7.91B	US#1,079/3,112 Sec#57/269
Revenue	$0.00	US#2,974/3,112 Sec#204/269
Net Income	$-506M	US—/3,112 Sec—/269
Total Assets	$957M	US#2,468/3,112 Sec#101/269
Net Assets	$853M	US#1,886/3,112 Sec#72/269
Value
P/B	9.27x	US#2,574/3,112 Sec#201/269
FCF Yield	-5.15%	US—/3,112 Sec—/269
Profitability
ROE	-59.30%	US#2,772/3,112 Sec#187/269
ROA	-52.83%	US#2,978/3,112 Sec#224/269
Financial Health
Debt Ratio	12.25%	US#137/3,112 Sec#59/269
Total Debt	$72000.00	US#2,971/3,112 Sec#261/269
FCF	$-407M	US#2,815/3,112 Sec#252/269
Cash	$902M	US#747/3,112 Sec#33/269
Current Ratio	9.09x	US#272/3,112 Sec#87/269
Performance
1Y Return	145.13%	US#175/3,112 Sec#54/269
1M Return	-0.72%	US#1,752/3,112 Sec#86/269
From 52W High	-6.60%	US#720/3,112 Sec#28/269
1Y MDD	-20.98%	US#766/3,112 Sec#32/269
Trading
Volume	685,906 shares	US#1,821/3,112 Sec#178/269
Trading Value	$26M	US#1,812/3,112 Sec#129/269
Per Share
EPS	$-2.56	US—/3,112 Sec—/269
BPS	$5.43	US#2,189/3,112 Sec#127/269